CM Management LLC Buys 50,000 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)

CM Management LLC boosted its stake in Coherus BioSciences, Inc. (NASDAQ:CHRS) by 2.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,050,000 shares of the biotechnology company’s stock after acquiring an additional 50,000 shares during the period. Coherus BioSciences accounts for 2.4% of CM Management LLC’s investment portfolio, making the stock its 13th largest holding. CM Management LLC owned about 1.77% of Coherus BioSciences worth $2,829,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its holdings in Coherus BioSciences by 1.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 976,857 shares of the biotechnology company’s stock worth $1,348,000 after purchasing an additional 12,530 shares in the last quarter. Steph & Co. acquired a new position in shares of Coherus BioSciences during the 4th quarter valued at $34,000. Systematic Financial Management LP acquired a new stake in shares of Coherus BioSciences in the 3rd quarter valued at about $28,000. FMR LLC grew its stake in Coherus BioSciences by 21.1% in the third quarter. FMR LLC now owns 225,113 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 39,204 shares during the period. Finally, Ieq Capital LLC bought a new stake in Coherus BioSciences during the 4th quarter valued at $68,000. Institutional investors and hedge funds own 72.82% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on CHRS shares. Robert W. Baird lifted their target price on Coherus BioSciences from $4.00 to $6.00 and gave the company an “outperform” rating in a research report on Thursday, December 5th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Coherus BioSciences in a report on Thursday, January 23rd. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $5.38.

Coherus BioSciences Trading Up 4.5 %

Shares of NASDAQ CHRS opened at $1.04 on Friday. The business has a 50-day moving average of $1.25 and a 200-day moving average of $1.19. The firm has a market capitalization of $120.53 million, a price-to-earnings ratio of -13.00 and a beta of 0.92. Coherus BioSciences, Inc. has a 12 month low of $0.66 and a 12 month high of $2.64.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.